Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
FOXO4
REST API REST API
Homo sapiens
FOXO4 is differentially expressed in 171 experiments: 92 organism parts: placenta, lung, ... (90 more);, 139 disease states: normal, Huntington's disease, ... (137 more);, 53 cell types 149 cell lines 12 compound treatments and 60 other conditions.
Synonyms MLLT7, AFX1
Orthologs FOXO4 (Danio rerio)   foxo (Drosophila melanogaster)   A6QLP0_BOVIN (Bos taurus)   FOXO4 (Gallus gallus)   Foxo4 (Mus musculus)   Foxo4 (Rattus norvegicus)   ENSCING00000016777 (Ciona intestinalis)   ENSCING00000016781 (Ciona intestinalis)   foxo4 (Xenopus laevis)   FOXO4 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term cytosol, pattern specification process, embryo development, DNA binding, protein binding, regulation of transcription, DNA-dependent, cytoplasm, double-stranded DNA binding, negative regulation of cell proliferation, transcription, DNA-dependent, cell cycle arrest, DNA bending activity, insulin receptor signaling pathway, G1 phase of mitotic cell cycle, transcription from RNA polymerase II promoter, fibroblast growth factor receptor signaling pathway, transcription factor binding, cell differentiation, sequence-specific DNA binding, cell cycle, positive regulation of transcription from RNA polymerase II promoter, tissue development, protein kinase binding, nucleus, muscle organ development, transcription factor complex, nucleoplasm, enzyme binding, positive regulation of transcription, DNA-dependent, negative regulation of angiogenesis, mitotic cell cycle G2/M transition DNA damage checkpoint, organ development, negative regulation of smooth muscle cell differentiation, nerve growth factor receptor signaling pathway, sequence-specific DNA binding transcription factor activity, phosphatidylinositol-mediated signaling, regulation of sequence-specific DNA binding transcription factor activity, sequence-specific distal enhancer binding RNA polymerase II transcription factor activity
InterPro Term TF_fork_head
UniProt Accession P98177
Search EB-eye ENSG00000184481
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-GEOD-6573, E-MEXP-1251, ... (21 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-1880, E-GEOD-22152, E-GEOD-22639, ... (22 experiments)

Factor Value U/D Experiments
BJAB
1
E-GEOD-1880
D341Med
1
E-MTAB-37
pc3
1
E-MTAB-62
NA18855
1
E-GEOD-19480
skmel5
1
E-MTAB-62
GM15510
1
E-GEOD-22639
143 more value(s).


Cell type

studied in E-GEOD-20193, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-13909, ... (29 experiments)

Factor Value U/D Experiments
platelet
1
E-GEOD-2006
n/a
1
E-MTAB-24
adipocyte
1
E-MTAB-25
granulocyte
1
E-MEXP-583
naive
1
E-GEOD-2649
Leukocytes
1
E-GEOD-21909
47 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-2466, E-GEOD-1869, E-MEXP-2069, E-GEOD-2549, ... (36 experiments)

Factor Value U/D Experiments
colon carcinoma
2
E-MTAB-62, E-MTAB-37
juvenile dermatomyositis
2
E-GEOD-3307, E-MTAB-62
lung adenocarcinoma
2
E-MTAB-62, E-MTAB-37
superficial transitional cell carcinoma with surrounding carcinoma in situ lesion
1
E-GEOD-3167
carcinoma in situ, bladder tumor
1
E-MTAB-62
uterine fibroid
1
E-GEOD-7307
133 more value(s).


Compound treatment

studied in E-GEOD-3284, E-GEOD-412, E-GEOD-2803, E-TABM-127, E-GEOD-5824, ... (8 experiments)

Factor Value U/D Experiments
none
4
E-GEOD-2803, E-GEOD-5824, E-GEOD-412, E-GEOD-7307
filtered air
1
E-TABM-127
4-hydroxytamoxifen
1
1
E-MEXP-2241
ethanol
4
1
E-MEXP-2241
Cxcl12
1
E-GEOD-7307
rapamycin
1
E-GEOD-5824
6 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cell treatment
studied in E-MEXP-1192

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-21374, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-GEOD-19743, E-GEOD-3140

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743

Environmental stress
studied in E-GEOD-1518

Estrogen receptor status
studied in E-GEOD-6532

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-MEXP-1482, E-MTAB-108, E-GEOD-6431 ... (5 experiments)

Genotype
studied in E-TABM-763, E-TABM-1029, E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, ... (8 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-GEOD-7011, E-GEOD-22278, E-GEOD-837

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276

Individual
studied in E-MTAB-197, E-TABM-325, E-GEOD-1926, E-GEOD-19330, E-TABM-666, ... (21 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-12254, E-MEXP-561, E-GEOD-17400

Injury
studied in E-GEOD-19743

Karyotype
studied in E-GEOD-7214

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

organ
studied in E-GEOD-24283

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

P53 ihc
studied in E-GEOD-21653

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-21750, E-GEOD-1460

Population
studied in E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-1343

RNAi
studied in E-MEXP-1509, E-MEXP-101, E-GEOD-3697

Sample preparation
studied in E-GEOD-16728

sample status
studied in E-GEOD-30573

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-20114

stimulus
studied in E-GEOD-22103

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-GEOD-1926, E-TABM-276

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, E-GEOD-15799, E-GEOD-12198 ... (5 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Ttf
studied in E-GEOD-21521

Tumor grading
studied in E-GEOD-4290

Tumor size
studied in E-GEOD-6532

Processing time: 0.451 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM